Myelodysplastic Syndromes (MDS)
What is Myelodysplastic Syndromes (MDS)?
Myelodysplastic syndromes are a group of bone marrow disorders where your body struggles to make healthy blood cells. Your bone marrow is the spongy tissue inside your bones that produces red blood cells, white blood cells, and platelets. In MDS, the bone marrow makes abnormal cells that don't work properly and often die earlier than normal cells.
This condition causes low blood counts and can lead to serious health problems. The abnormal cells crowd out healthy ones, leaving you with fewer working blood cells. MDS is sometimes called a clonal disorder because it starts from one abnormal cell that copies itself repeatedly.
MDS affects mostly older adults, with an average age of diagnosis around 70 years. Some forms of MDS are mild and slow moving, while others progress quickly. In about 30% of cases, MDS can transform into acute myeloid leukemia, a type of blood cancer. Early detection through regular blood testing helps doctors monitor disease progression and start treatment when needed.
Symptoms
- Fatigue and weakness that doesn't improve with rest
- Shortness of breath during normal activities
- Pale skin or looking unusually pale
- Easy bruising or unusual bruising patterns
- Frequent nosebleeds or bleeding gums
- Small red spots under the skin called petechiae
- Frequent infections or infections that won't heal
- Fever without an obvious cause
- Weight loss without trying
- Dizziness or feeling lightheaded
Many people with early MDS have no symptoms at all. The condition is often discovered during routine blood work done for other reasons. As MDS progresses, symptoms usually become more noticeable as blood counts drop lower.
Concerned about Myelodysplastic Syndromes (MDS)? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
MDS happens when DNA damage occurs in bone marrow stem cells, causing them to produce abnormal blood cells. In most cases, doctors can't identify a specific cause. This is called primary or de novo MDS. Age is the biggest risk factor, as cellular DNA damage accumulates over time. Exposure to certain chemicals like benzene increases risk, as does previous chemotherapy or radiation treatment for other cancers.
Secondary MDS develops after cancer treatment and typically appears 5 to 10 years after exposure. Smoking raises your risk of developing MDS. Some genetic conditions like Fanconi anemia and Down syndrome also increase susceptibility. Men develop MDS slightly more often than women. While family history can play a role, MDS is not directly inherited in most cases. Environmental toxins and industrial chemical exposure may contribute, though the link isn't always clear.
How it's diagnosed
MDS diagnosis starts with blood tests that measure your blood cell counts and examine cell appearance. Our flagship panel at Rite Aid tracks white blood cell count, platelet count, and monocyte levels. These biomarkers help identify the abnormal patterns characteristic of MDS. Low counts in one or more blood cell types often prompt further investigation.
If blood tests show abnormalities, your doctor will likely recommend a bone marrow biopsy. This procedure removes a small sample of bone marrow for examination under a microscope. Doctors look for dysplastic features, meaning cells with unusual shapes or structures. Genetic testing on bone marrow cells helps identify chromosomal changes that confirm MDS and predict how the disease may progress. Regular blood monitoring is essential for anyone at risk or showing early signs.
Treatment options
- Regular blood tests to monitor blood cell counts and disease progression
- Blood transfusions to treat severe anemia or low platelet counts
- Growth factor injections like erythropoietin to stimulate red blood cell production
- Azacitidine or decitabine medications to help bone marrow make normal cells
- Lenalidomide for specific MDS subtypes with certain genetic changes
- Stem cell transplant for younger patients with aggressive disease
- Iron chelation therapy if repeated transfusions cause iron overload
- Supportive care including antibiotics for infections
- Eating a nutrient-rich diet to support overall health
- Avoiding smoking and limiting alcohol consumption
Concerned about Myelodysplastic Syndromes (MDS)? Get tested at Rite Aid.
- Simple blood draw at your nearest lab
- Results in days, not weeks
- Share results with your doctor
Frequently asked questions
Early MDS often causes no noticeable symptoms. When symptoms appear, they usually include persistent fatigue, shortness of breath, and looking paler than usual. Many people first learn they have MDS through routine blood work that shows unexplained low blood counts. If you experience ongoing tiredness or unusual bruising, talk to your doctor about blood testing.
MDS is a bone marrow disorder where your body makes abnormal blood cells that don't mature properly. Leukemia is a blood cancer where abnormal cells multiply rapidly and crowd out healthy cells. MDS can transform into acute myeloid leukemia in about 30% of cases. Both conditions affect the bone marrow, but they progress differently and require different treatment approaches.
Yes, blood tests are the first step in detecting MDS. Tests measuring white blood cell count, platelet count, and monocyte levels reveal the abnormal patterns associated with this condition. Our flagship panel at Rite Aid includes these key biomarkers. If results show abnormalities, your doctor will recommend additional testing like a bone marrow biopsy to confirm diagnosis.
MDS primarily affects adults over 60, with the average diagnosis age around 70 years. People who received chemotherapy or radiation for previous cancers face higher risk. Exposure to chemicals like benzene, smoking, and certain genetic conditions also increase susceptibility. Men develop MDS slightly more often than women.
Stem cell transplant is currently the only potential cure for MDS, but it's a high-risk procedure typically reserved for younger, healthier patients. For most people, treatment focuses on managing symptoms, improving blood counts, and slowing disease progression. Many patients live for years with proper monitoring and treatment. Your prognosis depends on MDS subtype, genetic changes, and overall health.
Testing frequency depends on your specific MDS type and risk level. Many patients need blood tests every 2 to 4 weeks initially to monitor cell counts and disease activity. Once your condition stabilizes, testing may spread to every 1 to 3 months. Your doctor will create a monitoring schedule based on your individual needs and treatment plan.
While lifestyle changes can't cure MDS, they support overall health and may improve quality of life. Eating a nutrient-rich diet helps your body function better despite low blood counts. Avoiding smoking and limiting alcohol reduces additional stress on your bone marrow. Getting adequate rest and preventing infections through good hygiene are also important for managing this condition.
Low platelet counts occur in 40% to 60% of MDS cases and indicate your bone marrow isn't producing enough platelets. Platelets help your blood clot, so low levels cause easy bruising, prolonged bleeding, and small red spots under your skin. Platelet count is used both for diagnosing MDS and assessing disease severity. Very low counts may require platelet transfusions.
No, MDS does not always progress to leukemia. About 30% of MDS cases transform into acute myeloid leukemia over time. The remaining 70% of patients manage the condition long-term without leukemia developing. Your transformation risk depends on MDS subtype, specific genetic changes, and severity scores. Regular monitoring helps doctors detect early signs of progression.
Azacitidine and decitabine are common medications that help bone marrow produce more normal cells. Lenalidomide works for specific MDS subtypes with certain genetic deletions. Erythropoietin and similar growth factors stimulate red blood cell production in some patients. Your doctor chooses medications based on your MDS type, risk level, and which blood counts are most affected.